BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 16596196)

  • 1. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
    Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
    Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
    Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
    Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
    Ishibashi M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Fukumoto M; Miyazaki K
    Clin Cancer Res; 2008 May; 14(10):3149-55. PubMed ID: 18483383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray.
    Sakamoto M; Kondo A; Kawasaki K; Goto T; Sakamoto H; Miyake K; Koyamatsu Y; Akiya T; Iwabuchi H; Muroya T; Ochiai K; Tanaka T; Kikuchi Y; Tenjin Y
    Hum Cell; 2001 Dec; 14(4):305-15. PubMed ID: 11925933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
    Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
    Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines.
    Duan Z; Lamendola DE; Duan Y; Yusuf RZ; Seiden MV
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):277-85. PubMed ID: 15565326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Gene expression profiling of human ovarian epithelial tumors by digo nucleotide microarray].
    Konno R
    Hum Cell; 2001 Dec; 14(4):261-6. PubMed ID: 11925926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
    Kumar A; Soprano DR; Parekh HK
    Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line.
    Lamendola DE; Duan Z; Yusuf RZ; Seiden MV
    Cancer Res; 2003 May; 63(9):2200-5. PubMed ID: 12727840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
    George JA; Chen T; Taylor CC
    Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.
    Duan Z; Feller AJ; Penson RT; Chabner BA; Seiden MV
    Clin Cancer Res; 1999 Nov; 5(11):3445-53. PubMed ID: 10589757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GBP1 overexpression is associated with a paclitaxel resistance phenotype.
    Duan Z; Foster R; Brakora KA; Yusuf RZ; Seiden MV
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):25-33. PubMed ID: 16028104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
    Yamamoto K; Kikuchi Y; Kudoh K; Nagata I
    J Cancer Res Clin Oncol; 2000 Mar; 126(3):168-72. PubMed ID: 10741911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
    Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
    Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
    Akervall J; Guo X; Qian CN; Schoumans J; Leeser B; Kort E; Cole A; Resau J; Bradford C; Carey T; Wennerberg J; Anderson H; Tennvall J; Teh BT
    Clin Cancer Res; 2004 Dec; 10(24):8204-13. PubMed ID: 15623595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression.
    Lu L; Katsaros D; Wiley A; de la Longrais IA; Puopolo M; Yu H
    Cancer Invest; 2008 Mar; 26(2):185-92. PubMed ID: 18259951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior.
    Canet B; Pons C; Espinosa I; Prat J
    Hum Pathol; 2011 Jun; 42(6):833-9. PubMed ID: 21208644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.
    Duan Z; Foster R; Bell DA; Mahoney J; Wolak K; Vaidya A; Hampel C; Lee H; Seiden MV
    Clin Cancer Res; 2006 Sep; 12(17):5055-63. PubMed ID: 16951221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells.
    Buys TP; Chari R; Lee EH; Zhang M; MacAulay C; Lam S; Lam WL; Ling V
    Genes Chromosomes Cancer; 2007 Dec; 46(12):1069-79. PubMed ID: 17726699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.